Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.

dc.creatorGarcia, Laura Ramírez
dc.creatorSantos, Diego Moura
dc.creatorSouza, Ana Paula Almeida de
dc.creatorCoelho, Eduardo Antonio Ferraz
dc.creatorBarral, Aldina Maria Prado
dc.creatorAlonso, Carlos
dc.creatorEscutia, Marta R
dc.creatorBonay, Pedro
dc.creatorOliveira, Camila Indiani de
dc.creatorAlvarez, Manuel Soto
dc.date2014-09-19T19:36:54Z
dc.date2014-09-19T19:36:54Z
dc.date2013
dc.date.accessioned2023-09-26T21:11:21Z
dc.date.available2023-09-26T21:11:21Z
dc.identifierGARCIA, L. R. et al. Evaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis. Vaccine, v. 31, n. 9, p. 1312-1319, 2013.
dc.identifier1873-2518
dc.identifierhttps://www.arca.fiocruz.br/handle/icict/8409
dc.identifier10.1016/j.vaccine.2012.12.071
dc.identifier.urihttps://repositorioslatinoamericanos.uchile.cl/handle/2250/8870555
dc.descriptionFour new antigenic proteins located in Leishmania ribosomes have been characterized: S4, S6, L3 and L5. Recombinant versions of the four ribosomal proteins from Leishmania major were recognized by sera from human and canine patients suffering different clinical forms of leishmaniasis. The prophylactic properties of these proteins were first studied in the experimental model of cutaneous leishmaniasis caused by L. major inoculation into BALB/c mice. The administration of two of them, LmL3 or LmL5 combined with CpG-oligodeoxynucleotides (CpG-ODN) was able to protect BALB/c mice against L. major infection. Vaccinated mice showed smaller lesions and parasite burden compared to mice inoculated with vaccine diluent or vaccine adjuvant. Protection was correlated with an antigen-specific increased production of IFN-γ paralleled by a decrease of the antigen-specific IL-10 mediated response in protected mice relative to non-protected controls. Further, it was demonstrated that BALB/c mice vaccinated with recombinant LmL3 or LmL5 plus CpG-ODN were also protected against the development of cutaneous lesions following inoculation of L. braziliensis. Together, data presented here indicate that LmL3 or LmL5 ribosomal proteins combined with Th1 inducing adjuvants, may be relevant components of a vaccine against cutaneous leishmaniasis caused by distinct species.
dc.formatapplication/pdf
dc.languageeng
dc.publisherElsevier Ltd
dc.rightsopen access
dc.subjectLeishmania
dc.subjectBALB/c mice
dc.subjectTh1/Th2 Immune responses
dc.subjectRecombinant ribosomal proteins
dc.subjectVaccines
dc.subjectLeishmania major/imunologia
dc.subjectVacinas contra Leishmaniose/imunologia
dc.subjectLeishmaniose Cutânea/prevenção & controle
dc.subjectProteínas Ribossômicas/imunologia
dc.subjectAdjuvantes Imunológicos/administração & dosagem
dc.subjectAnimais
dc.subjectModelos Animais de Doenças
dc.subjectFeminino
dc.subjectInterferon gama/secreção
dc.subjectLeishmania braziliensis/imunologia
dc.subjectVacinas contra Leishmaniose/administração & dosagem
dc.subjectLeishmaniose Cutânea/imunologia
dc.subjectLeucócitos Mononucleares/imunologia
dc.subjectCamundongos
dc.subjectCamundongos Endogâmicos BALB C
dc.subjectOligodesoxirribonucleotídeos/administração & dosagem
dc.subjectProteínas Recombinantes/genética
dc.subjectVacinas Sintéticas/administração & dosagem
dc.titleEvaluation of immune responses and analysis of the effect of vaccination of the Leishmania major recombinant ribosomal proteins L3 or L5 in two different murine models of cutaneous leishmaniasis.
dc.typeArticle


Este ítem pertenece a la siguiente institución